Salud
US to donate 1 million doses of mpox vaccine to curb African outbreak
US President Joe Biden on Tuesday announced the donation of one million doses of mpox vaccine and at least $500 million to African countries to
Eli Lilly’s Alzheimer’s drug approved in Japan
Japan’s Ministry of Health has approved Eli Lilly’s Alzheimer’s drug donanemab, giving patients another treatment option after Eisai and Biogen’s Leqembi received the go-ahead in
Novo Nordisk faces US scrutiny over drug prices
US Senator Bernie Sanders is set to grill Novo Nordisk CEO Lars Jorgensen over the prices of Wegovy, the weight loss and diabetes drug, which
US to donate 1 million doses of mpox vaccine to curb African outbreak
US President Joe Biden on Tuesday announced the donation of one million doses of mpox vaccine and at least $500 million to African countries to
India reports first mpox case of new clade 1b variety
India said a case of mpox involving a traveller in the southern state of Kerala was of the fast-spreading clade 1b variety, marking the country’s
AstraZeneca’s experimental drug disappoints in breast cancer survival trial
AstraZeneca said its experimental precision drug, developed with Japan’s Daiichi Sankyo, significantly improved overall survival for patients with a type of breast cancer in a
WHO says nearly 30,000 suspected cases of mpox in Africa this year
Nearly 30,000 suspected cases of mpox have been reported in Africa so far this year, most of them in the Democratic Republic of Congo, the
EU regulator backs use of Wegovy for obesity-related heart disease
The European Medicines Agency has backed the use of Novo Nordisk’s vaccine, the popular drug Wegovy, to help relieve heart failure in people with obesity,
Appeals court revives challenge to US drug price negotiation programme
A US appeals court revived a lawsuit filed by pharmaceutical and health industry groups challenging the first US law requiring drug companies to negotiate drug
US FTC sues drug ‘watchdogs’ over high insulin prices
The US Federal Trade Commission sued the country’s three largest pharmacy benefit managers, accusing them of steering diabetic patients toward higher-priced insulin to obtain millions